Hepatotoxicity in 2011 - Advancing resolutely

Revista Espanola de Enfermedades Digestivas

Volumn 103, Issue 9, 2011, Pages 472-479

  Lozano Lanagrán, Marta ^a   Robles, Mercedes ^a   Lucena, María Isabel ^b   Andrade, Raúl J ^a  

^a UNIVERSIDAD DE MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER B11; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; BILIRUBIN; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CHINESE DRUG; DISULFIRAM; DNA DIRECTED DNA POLYMERASE GAMMA; FLUCLOXACILLIN; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; HERBACEOUS AGENT; HLA B57 ANTIGEN; HORMONE; IMMUNOMODULATING AGENT; ISONIAZID; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

AGE; ALCOHOL CONSUMPTION; ARTICLE; CAUCASIAN; CIGARETTE SMOKING; CIOMS/RUCAM SCALE; CLINICAL DIAGNOSTIC SCALE; DISEASE CLASSIFICATION; FRANCE; HEREDITY; HUMAN; INCIDENCE; LIVER DISEASE; LIVER TOXICITY; LYMPHOCYTE TRANSFORMATION TEST; MARIA AND VICTORINO SCALE; MEDICAL ASSESSMENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NARANJO ADVERSE REACTION PROBABILITY SCALE; NEGRO; POLYPHARMACY; RACE DIFFERENCE; REYE SYNDROME; RISK FACTOR; SEX DIFFERENCE;

EID: 80054700724     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082011000900006     Document Type: Article

References (63)

1. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, et al. Incidence of drug-induced hepatic injuries: a French population based study. Hepatology 2002;36:451-455.
2. Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007;102:558-562.
3. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005;61:135-143.
4. Andrade RJ, Lucena MI, Fernández MC, Peláez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005;129:512-521.
5. Chalasani N, Fontana R, Bonkovsky MD, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934.
6. De Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58:71-80.
7. Hussaini SH, O'Brien CS, Despott EJ, Dalton JR. Antibiotic therapy: a major cause of drug-induced juandice in southwest England. Eur J Gastroenterol Hepatol 2007;19:15-20.
8. Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992;232:133-138.
9. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatology Res 2009;39:427-431.
10. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-2009.
11. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51:132-136.
12. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-385.
13. Heubi JE, Partin JC, Partin JS, Schubert WK. Reye's syndrome: current concepts. Hepatology 1987;7:155-164.
14. Hamer HM, Morris HH. Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants. Clev Clin J Med 1999;66:239-245.
15. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-819.
16. Hughes CA, Foisy MM, Dewhurst N, Higgins N, Robinson L, Kelly DV, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008;42:387-396.
17. Meier Y, Zodan T, Lang C, Zimmermann R, Kullak-Ublick GA, Meier PJ, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008;14:38-45.
18. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase gene POLG determines the risk of sodium valproate induced liver toxicity. Hepatology. 2010;52(5):1791-1796.
19. Lucena MI, Andrade RJ, Martinez C, Ulzurrun E, García-Martín E, Borraz Y, et al. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-596.
20. Andrade RJ, Salmerón J, Lucena MI. Drug hepatotoxicity. In: Reddy KJ, Faust T, editors. The Clinician's Guide to Liver Disease. New Jersey: SLACK Inc.; 2006. p. 321-343.
21. Bénichou C. Report of an International Consensus Meeting. Criteria of drug-induced liver disorders. J Hepatol 1990;11:272-276.
22. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury (DILI). Clin Pharmacol Ther 2011; (in press).
23. Fontana R, Seef L, Andrade RJ, Björnsson E, Day CP, Serrano J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010;52:730-742.
24. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481-489.
25. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001-2009.
26. Zimmerman HJ: Hepatotoxicity. The adverse effects of Drugs and Other Chemicals on the River. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
27. Andrade RJ, Lucena MI, Kaplowitz N, García-Muñoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44:1581-1588.
28. Borraz Y, Fernández MC, García-Muñoz B, Romero-Gómez M, Robles M, Durán JA, et al. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI)? Hepatology 2010;52(Supl.):457A.
29. Andrade RJ, Camargo R, Lucena MI, González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004;3:329-344.
30. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Peláez G, Durán JA, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006;44:850-856.
31. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010;463-470.
32. Fernández-Castañer A, García-Cortés M, Lucena MI, Borraz Y, Peláez G, Costa J, et al. An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event. Rev Esp Enferm Dig 2008;100:278-284.
33. Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists World J Gastroenterol 2007;13:329-340.
34. Goodman ZD. Drug hepatotoxicity. Clin Liver Dis 2002;6:381-397.
35. Kleiner DE. The pathology of drug-induced liver disease. Semin Liv Dis 2009;29:364-372.
36. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Path 2009;62:481-492.
37. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology- drug disposition, action and therapy in infants and children. N Engl J Med 2003;349:1157-1167.
38. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-206.
39. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. Isoniazidrifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-504.
40. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
41. Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, et al. Is the increased risk of liver enzyme elevation in patients coinfected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007;21:599-606.
42. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, Castellares C, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-676.
43. Maida I, Babudieri S, Selva C, D'Offizi G, Fenu L, Solinas G, et al. Liver enzyme elevation in hepatitis C virus (HCV): HIV co-infected patients prior and after initiation of HAART: role of HCV genotypes. AIDS Res Hum Retroviruses 2006;22:139-143.
44. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;128:1287-1292.
45. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-65.
46. Whiting-O'Keefe QE, Fyfe KH, Sack KD. Methotrexate and his tologic hepatic abnormalities: A meta-analysis. Am J Med 1991; 90:711.
47. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996;20:312(7024):169-172.
48. Peedikayil MC, Dahhan TI, Al-Ashgar HI. Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. Ann Pharmacother 2006;40(10):1888-1889.
49. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002;6(3):755-774.
50. Lucena MI, Kaplowitz N, Hallal H, Castiella A, García-Bengoechea M, Otazua P, et al. Recurrent drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry. The dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011; in press
51. García-Cortés M, Stephens C, Fernández-Castañer A, Lucena MI, Andrade RJ. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55(3):683-691.
52. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
53. Maria V, Victorino R. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-669.
54. Lucena MI, Camargo R, Andrade RJ, Pérez-Sánchez C, Sánchez de la Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123-130.
55. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-1183.
56. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000;33:949-952.
57. García-Cortes M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-789.
58. Takikawa H, Takamori Y, Kumagi T, Onji M, Watanabe M, Shibuya A, et al. Assessment of 387 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res 2003;27:192-195.
59. Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137(3):856-864.
60. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci 1991;36:1223-1228.
61. Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996;111:716-719.
62. Beyer TA, Xu W, Teupser D, Keller UAD, Bugnon P, Hildt E, et al. Impaired liver regeneration in Nrf2 knockout mice. EMBO J 2008; 27:212-223.
63. Mason AL, Luketic V, Lindor K, Hirschfield GM, Gordon SC, Mayo MJ, et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evalulating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 2010;52(Supl.):357A.